Martucci Matia, Russo Rosellina, Giordano Carolina, Schiarelli Chiara, D'Apolito Gabriella, Tuzza Laura, Lisi Francesca, Ferrara Giuseppe, Schimperna Francesco, Vassalli Stefania, Calandrelli Rosalinda, Gaudino Simona
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico "A. Gemelli" IRCCS, 00168 Rome, Italy.
Istituto di Radiologia, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Cancers (Basel). 2023 Jul 26;15(15):3790. doi: 10.3390/cancers15153790.
MRI plays a key role in the evaluation of post-treatment changes, both in the immediate post-operative period and during follow-up. There are many different treatment's lines and many different neuroradiological findings according to the treatment chosen and the clinical timepoint at which MRI is performed. Structural MRI is often insufficient to correctly interpret and define treatment-related changes. For that, advanced MRI modalities, including perfusion and permeability imaging, diffusion tensor imaging, and magnetic resonance spectroscopy, are increasingly utilized in clinical practice to characterize treatment effects more comprehensively. This article aims to provide an overview of the role of advanced MRI modalities in the evaluation of treated glioblastomas. For a didactic purpose, we choose to divide the treatment history in three main timepoints: post-surgery, during Stupp (first-line treatment) and at recurrence (second-line treatment). For each, a brief introduction, a temporal subdivision (when useful) or a specific drug-related paragraph were provided. Finally, the current trends and application of radiomics and artificial intelligence (AI) in the evaluation of treated GB have been outlined.
MRI在评估治疗后变化中起着关键作用,无论是在术后即刻还是随访期间。根据所选治疗方法和进行MRI检查的临床时间点,存在许多不同的治疗方案和许多不同的神经放射学表现。结构MRI往往不足以正确解释和界定与治疗相关的变化。为此,包括灌注和通透性成像、扩散张量成像以及磁共振波谱在内的先进MRI技术在临床实践中越来越多地被用于更全面地表征治疗效果。本文旨在概述先进MRI技术在评估经治疗的胶质母细胞瘤中的作用。出于教学目的,我们选择将治疗过程分为三个主要时间点:术后、Stupp方案(一线治疗)期间和复发时(二线治疗)。针对每个时间点,都提供了简要介绍、时间细分(如有必要)或特定的与药物相关的段落。最后,概述了放射组学和人工智能(AI)在评估经治疗的胶质母细胞瘤中的当前趋势和应用。